CHAMPIONS ONCOLOGY, INC. (CSBR) Return on equity 2018–2026
CHAMPIONS ONCOLOGY, INC. (CSBR) return on equity by fiscal year — reported net income divided by year-end shareholders’ equity.
-29.8%FY2026 · since FY2018: -49200.0% → -29.8%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2026 | -29.8% | -154.5 pp |
| FY2025 | 124.6% | — |
| FY2023 | -115.1% | -121.1 pp |
| FY2022 | 6.0% | +1.2 pp |
| FY2021 | 4.9% | +45.9 pp |
| FY2020 | -41.0% | -47.0 pp |
| FY2019 | 6.0% | +49206.0 pp |
| FY2018 | -49200.0% | — |
ROE = reported net income ÷ reported year-end shareholders’ equity for the same fiscal year. Heavy buybacks shrink equity and can push ROE very high (or negative-equity years drop out).
Source: SEC XBRL filings · For reference only · Not investment advice
More CSBR financial trends
CSBR RevenueCSBR Net incomeCSBR Net marginCSBR Gross profitCSBR Gross marginCSBR Operating incomeCSBR Operating marginCSBR Operating cash flowCSBR Free cash flowCSBR Capital expendituresCSBR Stock buybacksCSBR Dividends paidCSBR Total assetsCSBR Total liabilitiesCSBR Shareholders’ equityCSBR overview →